Aktienanalyse zu Milestone Scientific Inc (MLSS)MLSSMilestone Scientific Inc

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Milestone Scientific Inc is currently trading at $0.302, which is significantly below its 52-week high of $0.58, indicating potential for recovery. However, the RSI is at 42.26, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 18.21, indicating that the stock may be overvalued based on future earnings expectations. The company has shown revenue growth of 22% year-over-year in Q2 2026, but it still faces challenges with declining gross margins and negative net income, which was -$1,059,332 in Q2 2026. The main risk is the declining gross margin, which fell to 66.55% in Q2 2026, indicating increasing costs that could impact profitability.

1 analysts cover MLSS: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 1.00.